Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
201P - Isolation of circulating tumor cells and potential heterogeneity analysis in advanced non-small cell lung cancer (ID 148)
12:30 - 13:00 | Author(s): Q. Zhang
Liquid biopsy as a noninvasive testing method is attractive not only for evaluation of prognosis but also for detection of the molecular drivers of tumors and specific DNA mutations that predict a response or resistance to targeted agents in the era of personalized medicine. A tumor biopsy depicts only a single site, which might be inadequate for characterization of the tumor because of intratumoral and intermetastatic heterogeneity. Circulating tumor DNA offers a “real-time” tool for serial monitoring of tumor genomes by providing accessible genetic biomarkers for cancer diagnosis, prognosis, and response to therapy; thus, circulating tumor DNA has progressively become routinely used in clinical oncology, Another type of liquid biopsy focuses on analysis of, while circulating tumor cells (CTCs) which is potentially more practical for obtaining genome-wide information and facilitating heterogeneity analysis.
The CellSearch System is the only validated method for CTC detection that has been approved by the Food and Drug Administration. Based on this principle, we enrolled 60 patients with newly diagnosed and locally advanced or metastatic non-small cell lung cancer, CTCs were isolated by micromanipulation followed by whole-genome amplification, then analyzed by quantitative PCR for epidermal growth factor receptor (EGFR) mutation.
In 63% of these patients ≥1 CTC was isolated (median, 2 CTCs; range, 0–16 cells per 4.5 ml of blood). We then investigated whether the captured CTCs were suitable for molecular characterization. In five of six patients, the ampliﬁed CTC genomic DNA was further analyzed that proved with copy number variation. Three of these patients (1,3, and 5 CTCs, respectively) in whom the mutational status of the primary tumor was known showed speciﬁc EGFR mutations possibly identical to those of the primary tumor, while only one showed exactly the same mutation and the others showed clearly different mutations from the primary tumor.
These preliminary results suggest that the use of CTCs may be feasible for heterogeneity analysis of tumor mutations.
Clinical trial identification:
Legal entity responsible for the study:
Hongtao Zhang, Shucai Zhang
Capital features – Multicentre clinical study of Ectipitidine Hydrochloride in the Treatment of Advanced Lung Cancer with EGFR21 Exon Sensitive Mutation(Z161100000516107) Beijing Municipal Science and Technology Commission (Z151100004015104)
All authors have declared no conflicts of interest.